Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.9751
+0.0326 (3.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
93.90M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IMUX News
- 8 days ago - Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PRNewsWire
- 10 days ago - Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PRNewsWire
- 18 days ago - Immunic, Inc. to Participate in Scientific and Industry Conferences in April - PRNewsWire
- 6 weeks ago - Immunic to Participate in Scientific and Investor Conferences in March - PRNewsWire
- 7 weeks ago - Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - PRNewsWire
- 2 months ago - Immunic to Participate in Investor and Scientific Conferences in February - PRNewsWire
- 3 months ago - Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PRNewsWire